首页 > 最新文献

Terapevticheskii Arkhiv最新文献

英文 中文
[Radiation-induced intestinal injury]. [辐射引起的肠道损伤]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-26 DOI: 10.26442/00403660.2025.02.203116
A I Parfenov, L K Indejkina, E A Sabelnikova, A V Leontiev, A A Makarova

This article addresses theoretical and clinical aspects of radiation-induced intestinal injuries, which complicate radiation therapy for malignant neoplasms of the abdominal and pelvic organs. Many clinical aspects of this issue remain unknown due to the lack of awareness among doctors and patients. Further study of radiation-induced intestinal injuries and the development of personalized approaches to their prevention and treatment represent a relevant direction in internal medicine.

本文从理论和临床两方面阐述了辐射引起的肠道损伤,这使腹部和盆腔器官恶性肿瘤的放射治疗复杂化。由于医生和患者缺乏认识,这个问题的许多临床方面仍然未知。进一步研究辐射引起的肠道损伤,开发个性化的预防和治疗方法是内科学研究的一个相关方向。
{"title":"[Radiation-induced intestinal injury].","authors":"A I Parfenov, L K Indejkina, E A Sabelnikova, A V Leontiev, A A Makarova","doi":"10.26442/00403660.2025.02.203116","DOIUrl":"https://doi.org/10.26442/00403660.2025.02.203116","url":null,"abstract":"<p><p>This article addresses theoretical and clinical aspects of radiation-induced intestinal injuries, which complicate radiation therapy for malignant neoplasms of the abdominal and pelvic organs. Many clinical aspects of this issue remain unknown due to the lack of awareness among doctors and patients. Further study of radiation-induced intestinal injuries and the development of personalized approaches to their prevention and treatment represent a relevant direction in internal medicine.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 2","pages":"101-108"},"PeriodicalIF":0.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Evolution of enterology as a science]. [肠病学作为一门科学的演变]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-03-26 DOI: 10.26442/00403660.2025.02.203001
E A Sabelnikova, A V Kagramanova, O V Knyazev, S V Bykova, I N Ruchkina

The article discusses the main milestones in the development of enterology in the clinic of internal diseases. The review of the important stages of the study of diseases of the small and large intestine, its main achievements, discoveries resulting from the scientific and clinical work of outstanding Russian scientists. A deep understanding of pathological processes in diseases of the small intestine is discussed, diagnostic criteria and the possibility of identifying new nosological forms are considered.

本文讨论了肠病学在内科临床发展的主要里程碑。回顾小肠和大肠疾病研究的重要阶段,其主要成就,俄罗斯杰出科学家在科学和临床工作中的发现。在小肠疾病的病理过程的深刻理解进行了讨论,诊断标准和识别新的疾病形式的可能性被认为。
{"title":"[Evolution of enterology as a science].","authors":"E A Sabelnikova, A V Kagramanova, O V Knyazev, S V Bykova, I N Ruchkina","doi":"10.26442/00403660.2025.02.203001","DOIUrl":"https://doi.org/10.26442/00403660.2025.02.203001","url":null,"abstract":"<p><p>The article discusses the main milestones in the development of enterology in the clinic of internal diseases. The review of the important stages of the study of diseases of the small and large intestine, its main achievements, discoveries resulting from the scientific and clinical work of outstanding Russian scientists. A deep understanding of pathological processes in diseases of the small intestine is discussed, diagnostic criteria and the possibility of identifying new nosological forms are considered.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 2","pages":"214-218"},"PeriodicalIF":0.3,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical and anamnestic predictors of poor long-term prognosis in patients with chronic heart failure and implanted cardioverter-defibrillator]. [慢性心力衰竭和植入心脏转复除颤器患者长期预后不良的临床和记忆预测因素]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-21 DOI: 10.26442/00403660.2025.01.203045
N B Lebedeva, I V Talibullin, P G Parfenov, O L Barbarash

Aim: Identification of a complex of clinical and anamnestic predictors of an unfavorable long-term prognosis in patients with heart failure with low left ventricular ejection fraction and an implanted cardioverter-defibrillator (ICD).

Materials and methods: In 260 patients with heart failure with low left ventricular ejection fraction and ICD included in the "Kuzbass Register of Patients with ICD", data were obtained on the status of alive/dead, causes of death and cardiovascular events during a 4-year follow-up period. The clinical-instrumental and socio-demographic parameters entered into the register before ICD implantation were used to compile a prognostic regression model.

Results: A total of 348 cardiovascular events (endpoints) were recorded, of which 54 were deaths. The main cause of death in 48 (88.9%) patients was acute decompensated heart failure. According to the multivariate regression analysis, the factors that increase the risk of an unfavorable long-term outcome included in the prognostic model were: the level of systolic pressure in the pulmonary artery, the thickness of the interventricular septum, social status, the presence of chronic obstructive pulmonary disease, the low ejection fraction of the left ventricle and the absence of a renin-blocker angiotensin-aldosterone system (model sensitivity - 70%, specificity - 75.9%, AUC=0.8).

Conclusion: The use of a predictive model in clinical practice will make it possible to personalize approaches to making a decision on the need for ICD implantation and further monitoring of patients in order to improve their survival.

目的:确定低左室射血分数和植入心脏转复除颤器(ICD)的心力衰竭患者不良长期预后的临床和记忆预测因子的复合体。材料和方法:在“库兹巴斯ICD患者登记册”中纳入的260例左室射血分数低和ICD的心力衰竭患者中,在4年的随访期间获得了有关存活/死亡状态、死亡原因和心血管事件的数据。使用ICD植入前登记的临床仪器和社会人口学参数来编制预后回归模型。结果:共记录了348例心血管事件(终点),其中54例死亡。48例(88.9%)患者的主要死亡原因是急性失代偿性心力衰竭。根据多因素回归分析,预后模型中增加不良长期结局风险的因素有:肺动脉收缩压水平、室间隔厚度、社会地位、是否存在慢性阻塞性肺疾病、左心室射血分数低以及是否存在肾素阻滞剂血管紧张素-醛固酮系统(模型敏感性为70%,特异性为75.9%,AUC=0.8)。结论:在临床实践中使用预测模型将使个性化的方法来决定是否需要ICD植入和进一步监测患者,以提高患者的生存率。
{"title":"[Clinical and anamnestic predictors of poor long-term prognosis in patients with chronic heart failure and implanted cardioverter-defibrillator].","authors":"N B Lebedeva, I V Talibullin, P G Parfenov, O L Barbarash","doi":"10.26442/00403660.2025.01.203045","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203045","url":null,"abstract":"<p><strong>Aim: </strong>Identification of a complex of clinical and anamnestic predictors of an unfavorable long-term prognosis in patients with heart failure with low left ventricular ejection fraction and an implanted cardioverter-defibrillator (ICD).</p><p><strong>Materials and methods: </strong>In 260 patients with heart failure with low left ventricular ejection fraction and ICD included in the \"Kuzbass Register of Patients with ICD\", data were obtained on the status of alive/dead, causes of death and cardiovascular events during a 4-year follow-up period. The clinical-instrumental and socio-demographic parameters entered into the register before ICD implantation were used to compile a prognostic regression model.</p><p><strong>Results: </strong>A total of 348 cardiovascular events (endpoints) were recorded, of which 54 were deaths. The main cause of death in 48 (88.9%) patients was acute decompensated heart failure. According to the multivariate regression analysis, the factors that increase the risk of an unfavorable long-term outcome included in the prognostic model were: the level of systolic pressure in the pulmonary artery, the thickness of the interventricular septum, social status, the presence of chronic obstructive pulmonary disease, the low ejection fraction of the left ventricle and the absence of a renin-blocker angiotensin-aldosterone system (model sensitivity - 70%, specificity - 75.9%, AUC=0.8).</p><p><strong>Conclusion: </strong>The use of a predictive model in clinical practice will make it possible to personalize approaches to making a decision on the need for ICD implantation and further monitoring of patients in order to improve their survival.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"21-28"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A systematic review on the safety and efficacy of metamizole sodium as a therapy for the treatment of fever in children and adults]. [关于安美唑钠治疗儿童和成人发热的安全性和有效性的系统综述]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-21 DOI: 10.26442/00403660.2025.01.203101
A G Malyavin, S L Babak, A L Zaplatnikov, V А Bulgakova, M Y Garusova, M D Ilyukhina

Aim: To systematically analyze existing publications from available scientific databases (PubMed, Cochrane, eLibrary) for the period from 2018 to 2023 on the treatment of fever in children and adults with metamizole sodium (MS).

Materials and methods: A systematic review of scientific publications on the efficacy and safety of MS therapy for fever in adults and children compared to non-steroidal anti-inflammatory drugs was conducted. Six randomized clinical trials involving 884 patients (101 adults and 783 children) were included in the analysis.

Results: In all studies, MS has been demonstrated to be effective in reducing fever in both children and adults when used for short-term therapy. MS is superior to paracetamol, ibuprofen, acetylsalicylic acid and not inferior to nimesulide and propacetamol in terms of effectiveness in reducing body temperature between 1.5 and 6.0 hours after oral intake. It has been shown that treatment of fever with MS is a safer strategy compared to other non-steroidal anti-inflammatory drugs, as it has no clinically significant risks of gastric mucosal irritation, development of gastrointestinal bleeding and erosions. It has been established that therapeutic doses of MS do not lead to an increase in blood pressure, and in some cases contribute to hypotensive effect, especially in fever in adult comorbid patients with arterial hypertension.

Conclusion: MS is an effective treatment for fever in children and adults.

目的:系统分析现有科学数据库(PubMed, Cochrane, library)中2018 - 2023年关于使用metamizole钠(MS)治疗儿童和成人发热的现有出版物。材料和方法:系统回顾了与非甾体抗炎药相比,MS治疗成人和儿童发热的有效性和安全性的科学出版物。6项随机临床试验涉及884例患者(101例成人和783例儿童)纳入分析。结果:在所有的研究中,MS已被证明在儿童和成人的短期治疗中都能有效地退烧。MS在口服后1.5 ~ 6.0小时内降低体温的效果优于扑热息痛、布洛芬、乙酰水杨酸,不低于尼美舒利和丙帕他莫。研究表明,与其他非甾体类抗炎药相比,治疗发热伴多发性硬化症是一种更安全的策略,因为它没有临床显著的胃粘膜刺激、胃肠道出血和糜烂的风险。已经确定,治疗剂量的MS不会导致血压升高,在某些情况下有助于降压作用,特别是在伴有动脉高血压的成人合并症患者发烧时。结论:MS是治疗儿童和成人发热的有效方法。
{"title":"[A systematic review on the safety and efficacy of metamizole sodium as a therapy for the treatment of fever in children and adults].","authors":"A G Malyavin, S L Babak, A L Zaplatnikov, V А Bulgakova, M Y Garusova, M D Ilyukhina","doi":"10.26442/00403660.2025.01.203101","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203101","url":null,"abstract":"<p><strong>Aim: </strong>To systematically analyze existing publications from available scientific databases (PubMed, Cochrane, eLibrary) for the period from 2018 to 2023 on the treatment of fever in children and adults with metamizole sodium (MS).</p><p><strong>Materials and methods: </strong>A systematic review of scientific publications on the efficacy and safety of MS therapy for fever in adults and children compared to non-steroidal anti-inflammatory drugs was conducted. Six randomized clinical trials involving 884 patients (101 adults and 783 children) were included in the analysis.</p><p><strong>Results: </strong>In all studies, MS has been demonstrated to be effective in reducing fever in both children and adults when used for short-term therapy. MS is superior to paracetamol, ibuprofen, acetylsalicylic acid and not inferior to nimesulide and propacetamol in terms of effectiveness in reducing body temperature between 1.5 and 6.0 hours after oral intake. It has been shown that treatment of fever with MS is a safer strategy compared to other non-steroidal anti-inflammatory drugs, as it has no clinically significant risks of gastric mucosal irritation, development of gastrointestinal bleeding and erosions. It has been established that therapeutic doses of MS do not lead to an increase in blood pressure, and in some cases contribute to hypotensive effect, especially in fever in adult comorbid patients with arterial hypertension.</p><p><strong>Conclusion: </strong>MS is an effective treatment for fever in children and adults.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"71-79"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria]. [伊普他科泮单药治疗突发性夜间血红蛋白尿患者依曲单抗次优反应的疗效]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-21 DOI: 10.26442/00403660.2025.01.203146
O U Klimova, I K Golubovskaya, Y N Kuznetsov, M V Marchenko, A D Kulagin

Aim: To evaluate the hematological response within 4 weeks of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to long-term eculizumab therapy.

Materials and methods: The analysis included 8 patients, median age 32 years, with persistent anemia on long-term therapy with eculizumab. The hematological response was assessed when switching to oral monotherapy with iptacopan 200 mg twice daily for 4 weeks.

Results: After 4 weeks of iptacopan therapy, an increase in hemoglobin levels by more than 20 g/l was achieved in 7/8 (88%), and a complete response in 6/8 (75%) patients. The median increase in hemoglobin levels was 32.5 g/l from the initial 85.5 g/l (74-100) to 121.5 g/l (80-141); p=0.00013. Independence from red blood cell transfusions was achieved in 100% of cases. Achieving a hematological response to iptacopan therapy was accompanied by a decrease in the level of absolute reticulocyte count, bilirubin and lactate dehydrogenase, as well as a negative result of the anti-C3d direct antiglobulin test.

Conclusion: The oral complement factor B inhibitor iptacopan is an effective treatment option for paroxysmal nocturnal hemoglobinuria in patients with a suboptimal response to complement inhibitor C5 due to more effective control of extravascular C3-mediated hemolysis.

目的:评价阵发性夜间血红蛋白尿患者伊普他科泮单药治疗4周内的血液学反应,以及长期埃珠单抗治疗的次优反应。材料和方法:本研究纳入8例长期接受eculizumab治疗的持续性贫血患者,中位年龄32岁。当切换到口服单药伊普他泮200mg,每日两次,持续4周时,评估血液学反应。结果:伊他科泮治疗4周后,7/8(88%)患者血红蛋白水平升高超过20 g/l, 6/8(75%)患者完全缓解。血红蛋白水平中位数从最初的85.5 g/l(74-100)增加到121.5 g/l(80-141),增加了32.5 g/l;p = 0.00013。100%的病例实现了红细胞输注的独立性。对伊普他科潘治疗的血液学反应伴随着网状红细胞绝对计数、胆红素和乳酸脱氢酶水平的下降,以及抗c3d直接抗球蛋白试验的阴性结果。结论:补体因子B抑制剂伊普他科泮口服补体因子B抑制剂伊普他科泮对补体抑制剂C5反应不佳的患者可有效控制血管外c3介导的溶血,是治疗突发性夜间血红蛋白尿的有效选择。
{"title":"[Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria].","authors":"O U Klimova, I K Golubovskaya, Y N Kuznetsov, M V Marchenko, A D Kulagin","doi":"10.26442/00403660.2025.01.203146","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203146","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the hematological response within 4 weeks of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to long-term eculizumab therapy.</p><p><strong>Materials and methods: </strong>The analysis included 8 patients, median age 32 years, with persistent anemia on long-term therapy with eculizumab. The hematological response was assessed when switching to oral monotherapy with iptacopan 200 mg twice daily for 4 weeks.</p><p><strong>Results: </strong>After 4 weeks of iptacopan therapy, an increase in hemoglobin levels by more than 20 g/l was achieved in 7/8 (88%), and a complete response in 6/8 (75%) patients. The median increase in hemoglobin levels was 32.5 g/l from the initial 85.5 g/l (74-100) to 121.5 g/l (80-141); <i>p</i>=0.00013. Independence from red blood cell transfusions was achieved in 100% of cases. Achieving a hematological response to iptacopan therapy was accompanied by a decrease in the level of absolute reticulocyte count, bilirubin and lactate dehydrogenase, as well as a negative result of the anti-C3d direct antiglobulin test.</p><p><strong>Conclusion: </strong>The oral complement factor B inhibitor iptacopan is an effective treatment option for paroxysmal nocturnal hemoglobinuria in patients with a suboptimal response to complement inhibitor C5 due to more effective control of extravascular C3-mediated hemolysis.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"46-53"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The effect of inflammatory bowel diseases on the risk of atherosclerosis: assessment according to ultrasound imaging and sphygmometry]. [炎症性肠病对动脉粥样硬化风险的影响:根据超声成像和血压计评估]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-21 DOI: 10.26442/00403660.2025.01.203028
G O Isaev, O I Trushina, M A Isaikina, A A Bestavashvili, M V Yurazh, P Y Kopylov, M H Mnatsakanyan, V V Fomin

Aim: To evaluate the effect of inflammatory bowel disease (IBD) on the risk of atherosclerosis in patients without known cardiovascular disease.

Materials and methods: The study included 115 patients divided into three groups: 37 patients with Crohn's disease (CD), 44 with ulcerative colitis (UC), and 34 in the control group without known IBD and other risk factors. Doppler ultrasound of the brachiocephalic arteries and sphygmometry were used for diagnosis. The main indicators were the thickness of the intima-media complex (TIMC) and vascular stiffness, measured by the cardio-ankle vascular index (CAVI) and the ankle-brachial pressure index (ABI).

Results: IBD patients showed an increase in TIMC compared to controls. TIMC of the common carotid arteries on the right: in patients with CD - 0.07 cm (p=0.001), with UC - 0.08 cm (p=0.019), in the control group - 0.06 cm. TIMC of the common carotid arteries on the left: in patients with CD - 0.07 cm (p=0.001), with UC - 0.07 cm (p=0.012), in the control group - 0.06 cm. The sphygmometry indicators (CAVI and ABI) did not differ significantly between the groups. The mean CAVI on the right was 6.8±0.98 for the CD group, 6.6±0.79 for the UC group, and 6.82±0.76 for the control group (p=0.692).

Conclusion: IBD can contribute to the thickening of the vascular walls, thus increasing the risk of atherosclerosis, as shown by TIMC. Vascular stiffness indicators (CAVI, ABI) did not differ significantly between the groups.

目的:评价炎症性肠病(IBD)对无已知心血管疾病患者动脉粥样硬化风险的影响。材料和方法:研究纳入115例患者,分为3组:克罗恩病(CD)患者37例,溃疡性结肠炎(UC)患者44例,对照组34例,无已知IBD及其他危险因素。采用多普勒头臂动脉超声和血压计进行诊断。主要指标为内膜-中膜复合体厚度(TIMC)和血管刚度,通过心-踝血管指数(CAVI)和踝-肱压力指数(ABI)测量。结果:与对照组相比,IBD患者TIMC升高。右侧颈总动脉TIMC: CD组- 0.07 cm (p=0.001), UC组- 0.08 cm (p=0.019),对照组- 0.06 cm。左侧颈总动脉TIMC: CD组- 0.07 cm (p=0.001), UC组- 0.07 cm (p=0.012),对照组- 0.06 cm。两组间血压计指标(CAVI和ABI)无显著差异。右侧CAVI平均值CD组为6.8±0.98,UC组为6.6±0.79,对照组为6.82±0.76 (p=0.692)。结论:TIMC显示IBD可导致血管壁增厚,从而增加动脉粥样硬化的风险。血管硬度指标(CAVI, ABI)组间无显著差异。
{"title":"[The effect of inflammatory bowel diseases on the risk of atherosclerosis: assessment according to ultrasound imaging and sphygmometry].","authors":"G O Isaev, O I Trushina, M A Isaikina, A A Bestavashvili, M V Yurazh, P Y Kopylov, M H Mnatsakanyan, V V Fomin","doi":"10.26442/00403660.2025.01.203028","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203028","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the effect of inflammatory bowel disease (IBD) on the risk of atherosclerosis in patients without known cardiovascular disease.</p><p><strong>Materials and methods: </strong>The study included 115 patients divided into three groups: 37 patients with Crohn's disease (CD), 44 with ulcerative colitis (UC), and 34 in the control group without known IBD and other risk factors. Doppler ultrasound of the brachiocephalic arteries and sphygmometry were used for diagnosis. The main indicators were the thickness of the intima-media complex (TIMC) and vascular stiffness, measured by the cardio-ankle vascular index (CAVI) and the ankle-brachial pressure index (ABI).</p><p><strong>Results: </strong>IBD patients showed an increase in TIMC compared to controls. TIMC of the common carotid arteries on the right: in patients with CD - 0.07 cm (<i>p</i>=0.001), with UC - 0.08 cm (<i>p</i>=0.019), in the control group - 0.06 cm. TIMC of the common carotid arteries on the left: in patients with CD - 0.07 cm (<i>p</i>=0.001), with UC - 0.07 cm (<i>p</i>=0.012), in the control group - 0.06 cm. The sphygmometry indicators (CAVI and ABI) did not differ significantly between the groups. The mean CAVI on the right was 6.8±0.98 for the CD group, 6.6±0.79 for the UC group, and 6.82±0.76 for the control group (<i>p</i>=0.692).</p><p><strong>Conclusion: </strong>IBD can contribute to the thickening of the vascular walls, thus increasing the risk of atherosclerosis, as shown by TIMC. Vascular stiffness indicators (CAVI, ABI) did not differ significantly between the groups.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"29-34"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[New pathogenic mutation in LMNA gene: Clinical case of familial cardiomyopathy]. 【家族性心肌病临床一例】。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-21 DOI: 10.26442/00403660.2025.01.203030
S Y Kashtanova, E М Rimskaya, A N Meshkov, N А Mironova, I K Dzhumaniiazova, E A Zelenova, V V Daniel', M V Ivanov, D A Kashtanova, V S Yudin, A A Keskinov, S I Mitrofanov, A I Akinshina, Y N Vanyushina, S А Kraevoy, S M Yudin, S P Golitsyn

We present a clinical case of familial LMNA-associated cardiomyopathy, confirmed by whole genome sequencing. The typical for lamin-associated cardiomyopathy indicates pathogenic nature of the mutation in the first exon of LMNA gene, previously considered a mutation of unknown clinical significance. The presented clinical case demonstrates a radical change in patient treatment strategies in the context of the widespread introduction of molecular genetic research methods into practice.

我们提出一个临床病例家族性lmna相关的心肌病,证实了全基因组测序。典型的纤层蛋白相关性心肌病表明了LMNA基因第一外显子突变的致病性,以前认为这是一种未知临床意义的突变。所提出的临床病例表明,在分子遗传研究方法广泛引入实践的背景下,患者治疗策略发生了根本性的变化。
{"title":"[New pathogenic mutation in LMNA gene: Clinical case of familial cardiomyopathy].","authors":"S Y Kashtanova, E М Rimskaya, A N Meshkov, N А Mironova, I K Dzhumaniiazova, E A Zelenova, V V Daniel', M V Ivanov, D A Kashtanova, V S Yudin, A A Keskinov, S I Mitrofanov, A I Akinshina, Y N Vanyushina, S А Kraevoy, S M Yudin, S P Golitsyn","doi":"10.26442/00403660.2025.01.203030","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203030","url":null,"abstract":"<p><p>We present a clinical case of familial <i>LMNA</i>-associated cardiomyopathy, confirmed by whole genome sequencing. The typical for lamin-associated cardiomyopathy indicates pathogenic nature of the mutation in the first exon of <i>LMNA</i> gene, previously considered a mutation of unknown clinical significance. The presented clinical case demonstrates a radical change in patient treatment strategies in the context of the widespread introduction of molecular genetic research methods into practice.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"65-70"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial]. [在III期膝关节骨关节炎患者中使用未变性II型胶原蛋白的经验:一项多中心、前瞻性、双盲、安慰剂对照、随机试验]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-21 DOI: 10.26442/00403660.2025.01.203145
L I Alekseeva, N G Kashevarova, E A Taskina, E A Strebkova, T A Korotkova, E P Sharapova, N M Savushkina, A M Lila, N A Shostak, I I Nesterovich, V A Dedkova, V B Vasilyuk, N V Egorova, M A Leontyeva, S P Yakupova, I B Vinogradova, V N Sorotskaya, L I Shirokova, A V Rudakova

Introduction: Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment.

Aim: To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial.

Materials and methods: The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint.

Results: A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile.

Conclusion: Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.

目前治疗骨关节炎(OA)的策略是基于多模式的方法,包括药物和非药物方法。未变性鸡II型胶原蛋白(NK2)被认为对维持关节健康安全有效,可单独使用或与药物联合用于OA治疗。目的:在一项多中心、前瞻性、双盲、安慰剂对照的随机试验中,进一步评估含NK2的Artneo联合治疗III期膝关节OA患者与安慰剂的疗效。材料和方法:该研究包括来自俄罗斯联邦12个中心的212例患者,其中50例为放射学III期膝关节OA: 41例(82.0%)女性,9例(18.0%)男性,年龄44至75岁。使用交互式网络响应系统(IWRS),研究人群被随机分为两组:第一组(Artneo组)包括28名患者,每天服用一次药物1胶囊,持续180天;第二组(安慰剂组)包括22名患者,接受药物匹配的安慰剂,治疗方案与第一组相同。采用视觉模拟量表(Visual analogue Scale)、WOMAC指数、oos、EQ-5D生活质量问卷、非甾体类抗炎药的使用情况评估治疗效果。所有患者均对目标膝关节进行全血细胞计数、尿液分析、血液化学和超声检查。结果:一项前瞻性、双盲、安慰剂对照、随机试验表明,含有NK2的Artneo在所有研究参数上都明显优于安慰剂,改善了OA的所有临床表现:减轻疼痛和僵硬,改善关节功能和生活质量,并具有良好的安全性。结论:Artneo在包括III期膝关节OA患者在内的一般人群中显示出较高的疗效和安全性。
{"title":"[Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial].","authors":"L I Alekseeva, N G Kashevarova, E A Taskina, E A Strebkova, T A Korotkova, E P Sharapova, N M Savushkina, A M Lila, N A Shostak, I I Nesterovich, V A Dedkova, V B Vasilyuk, N V Egorova, M A Leontyeva, S P Yakupova, I B Vinogradova, V N Sorotskaya, L I Shirokova, A V Rudakova","doi":"10.26442/00403660.2025.01.203145","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203145","url":null,"abstract":"<p><strong>Introduction: </strong>Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment.</p><p><strong>Aim: </strong>To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial.</p><p><strong>Materials and methods: </strong>The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint.</p><p><strong>Results: </strong>A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile.</p><p><strong>Conclusion: </strong>Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"54-64"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Risk factors for new-onset diabetes after transplantation in kidney transplant recipients: own data and meta-analysis]. [肾移植受者移植后新发糖尿病的危险因素:自身数据和荟萃分析]。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-21 DOI: 10.26442/00403660.2025.01.203029
M S Novikova, L O Minushkina, O N Kotenko, D A Zateyshchikov, O I Boeva, S S Allazova, E M Shilov, O M Koteshkova, M B Antsiferov

Aim: To compare risk factors for new-onset diabetes after transplantation (NODAT) among renal transplant recipients (RTRs) from 1989 to 2018 in the City Clinical Hospital №52, with a systematic analysis of published studies on this topic.

Materials and methods: In a 30-year (1989-2018) retrospective study, we found statistically significant differences in age, gender, polycystic kidney disease, cadaveric kidney, cyclosporine, i-mTOR, and steroids between two groups of recipients with and without NODAT. Patients with NODAT were older, more male, more likely to have polycystic kidney disease and deceased donor kidneys, and more likely to be treated with cyclosporine, i-mTOR, and steroids (p<0.05). We conducted a meta-analysis to evaluate the impact of these indicators on the development of NODAT. MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials were searched for eligible case-control studies of risk factors for NODAT in RTRs published between 1990 and 2019. Meta-analysis of proportions was performed using the Freeman-Tukey transformation to calculate weighted summary proportions from a fixed and random effects model.

Results: A total of 13 case-control studies were included in the meta-analysis. Of the total 849 studies found, 13 were included in the systematic review and meta-analysis, including ours, with a total of n=6797 RTRs, of which n=1305 patients with NODAT and n=5492 without NODAT. A wide range of data was recorded for the analysis of the incidence of NODAT (6.5-50.7%), with an average of 17.9% (fixed model) or 24.3% (random model). The proportion of NODAT recorded in the Russian registry of the City Clinical Hospital №52 was lower (11.5%), however, the data in the analyzed studies were highly heterogeneous: I2=98.14%, 95% CI: from 97.61 to 98.55, p<0.0001, Begg's test (p=0.05) and Egger's test (p=0.01) do not exclude the presence of publication bias in this case. Data on NODAT risk factors were less heterogeneous. This meta-analysis showed that age, polycystic kidney disease, i-mTOR and steroid therapy were associated with NODAT, whereas gender, calcineurin inhibitor use, and cadaveric kidney were not. There was no evidence of selection bias in any of the cases.

Conclusion: Risk factors for NODAT in kidney transplant recipients include older age, polycystic kidney disease, i-mTOR and steroid therapy, which initiate a state of insulin resistance. To reduce the risk of NODAT, the possibility of modifying immunosuppression regimens and the use of drugs that reduce insulin resistance and have a nephroprotective effect in RTRs should be considered. Therefore, randomized studies are needed to evaluate SGLT2 inhibitor in RTRs.

目的:比较1989年至2018年第52市临床医院肾移植受者(RTRs)移植后新发糖尿病(NODAT)的危险因素,并对已发表的相关研究进行系统分析。材料和方法:在一项30年(1989-2018)的回顾性研究中,我们发现两组有和没有NODAT的受体在年龄、性别、多囊肾病、尸肾、环孢素、i-mTOR和类固醇方面存在统计学差异。NODAT患者年龄较大,多为男性,更有可能患有多囊肾病和已故供体肾脏,更有可能接受环孢素、i-mTOR和类固醇治疗(结果:荟萃分析共纳入13项病例对照研究。在总共849项研究中,13项纳入了系统评价和荟萃分析,包括我们的研究,共有n=6797个rtr,其中n=1305例患有NODAT, n=5492例未患有NODAT。为分析NODAT的发生率,我们记录了广泛的数据(6.5-50.7%),平均为17.9%(固定模型)或24.3%(随机模型)。在城市临床医院№52的俄罗斯登记中记录的NODAT比例较低(11.5%),然而,分析研究中的数据是高度异质性的:I2=98.14%, 95% CI:从97.61到98.55,pp=0.05), Egger检验(p=0.01)不排除在这种情况下存在发表偏倚。有关NODAT危险因素的数据异质性较小。这项荟萃分析显示,年龄、多囊肾病、i-mTOR和类固醇治疗与NODAT相关,而性别、钙调磷酸酶抑制剂的使用和尸肾无关。在任何情况下都没有选择偏差的证据。结论:肾移植受者发生NODAT的危险因素包括年龄较大、多囊肾病、i-mTOR和类固醇治疗,这些因素可引发胰岛素抵抗状态。为了降低NODAT的风险,应考虑修改免疫抑制方案的可能性,并在RTRs中使用降低胰岛素抵抗和具有肾保护作用的药物。因此,需要随机研究来评估SGLT2抑制剂在RTRs中的作用。
{"title":"[Risk factors for new-onset diabetes after transplantation in kidney transplant recipients: own data and meta-analysis].","authors":"M S Novikova, L O Minushkina, O N Kotenko, D A Zateyshchikov, O I Boeva, S S Allazova, E M Shilov, O M Koteshkova, M B Antsiferov","doi":"10.26442/00403660.2025.01.203029","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203029","url":null,"abstract":"<p><strong>Aim: </strong>To compare risk factors for new-onset diabetes after transplantation (NODAT) among renal transplant recipients (RTRs) from 1989 to 2018 in the City Clinical Hospital №52, with a systematic analysis of published studies on this topic.</p><p><strong>Materials and methods: </strong>In a 30-year (1989-2018) retrospective study, we found statistically significant differences in age, gender, polycystic kidney disease, cadaveric kidney, cyclosporine, i-mTOR, and steroids between two groups of recipients with and without NODAT. Patients with NODAT were older, more male, more likely to have polycystic kidney disease and deceased donor kidneys, and more likely to be treated with cyclosporine, i-mTOR, and steroids (<i>p</i><0.05). We conducted a meta-analysis to evaluate the impact of these indicators on the development of NODAT. MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials were searched for eligible case-control studies of risk factors for NODAT in RTRs published between 1990 and 2019. Meta-analysis of proportions was performed using the Freeman-Tukey transformation to calculate weighted summary proportions from a fixed and random effects model.</p><p><strong>Results: </strong>A total of 13 case-control studies were included in the meta-analysis. Of the total 849 studies found, 13 were included in the systematic review and meta-analysis, including ours, with a total of <i>n</i>=6797 RTRs, of which <i>n</i>=1305 patients with NODAT and <i>n</i>=5492 without NODAT. A wide range of data was recorded for the analysis of the incidence of NODAT (6.5-50.7%), with an average of 17.9% (fixed model) or 24.3% (random model). The proportion of NODAT recorded in the Russian registry of the City Clinical Hospital №52 was lower (11.5%), however, the data in the analyzed studies were highly heterogeneous: <i>I</i><sup>2</sup>=98.14%, 95% CI: from 97.61 to 98.55, <i>p</i><0.0001, Begg's test (<i>p</i>=0.05) and Egger's test (<i>p</i>=0.01) do not exclude the presence of publication bias in this case. Data on NODAT risk factors were less heterogeneous. This meta-analysis showed that age, polycystic kidney disease, i-mTOR and steroid therapy were associated with NODAT, whereas gender, calcineurin inhibitor use, and cadaveric kidney were not. There was no evidence of selection bias in any of the cases.</p><p><strong>Conclusion: </strong>Risk factors for NODAT in kidney transplant recipients include older age, polycystic kidney disease, i-mTOR and steroid therapy, which initiate a state of insulin resistance. To reduce the risk of NODAT, the possibility of modifying immunosuppression regimens and the use of drugs that reduce insulin resistance and have a nephroprotective effect in RTRs should be considered. Therefore, randomized studies are needed to evaluate SGLT2 inhibitor in RTRs.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"35-45"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[History of patient education for chronic diseases (with diabetes mellitus as an example): from an idea to the branch of modern medicine]. 慢性疾病患者教育史(以糖尿病为例):从一种观念到现代医学的分支。
IF 0.3 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-21 DOI: 10.26442/00403660.2025.01.203139
E V Surkova, I V Glinkina, O Y Gurova, D V Mamleeva, G R Galstyan

The article describes the history of the formation of therapeutic education as one of the most essential components of the treatment of chronic diseases, in particular diabetes. The varieties and methods of programs for patients existing in the Russian Federation are considered in detail.

这篇文章描述了治疗性教育作为治疗慢性疾病,特别是糖尿病的最重要组成部分之一的形成历史。详细考虑了俄罗斯联邦现有的患者方案的种类和方法。
{"title":"[History of patient education for chronic diseases (with diabetes mellitus as an example): from an idea to the branch of modern medicine].","authors":"E V Surkova, I V Glinkina, O Y Gurova, D V Mamleeva, G R Galstyan","doi":"10.26442/00403660.2025.01.203139","DOIUrl":"https://doi.org/10.26442/00403660.2025.01.203139","url":null,"abstract":"<p><p>The article describes the history of the formation of therapeutic education as one of the most essential components of the treatment of chronic diseases, in particular diabetes. The varieties and methods of programs for patients existing in the Russian Federation are considered in detail.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 1","pages":"86-93"},"PeriodicalIF":0.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Terapevticheskii Arkhiv
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1